![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
PP353 is an antibiotic formulation designed for intradiscal injection under image guidance to provide substantial antibiotic exposure at the infected site. It is being evaluated for the treatment of chronic lower back pain.
Lead Product(s): PP353
Therapeutic Area: Neurology Product Name: PP353
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2024
Details:
PP353 is a sustained release formulation of an antibiotic to treat the chronic disc infection, which is designed for intradiscal injection under image guidance.
Lead Product(s): PP353
Therapeutic Area: Musculoskeletal Product Name: PP353
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Micron Research Ltd
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 19, 2021